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a b s t r a c t
Objectives: To examine whether the case fatality rate (CFR) of COVID-19 decreased over time and whether
the COVID-19 testing rate is a driving factor for the changes if the CFR decreased.
Methods: Analyzing COVID-19 cases, deaths and tests in Ontario, Canada, we compared the CFR between
the ﬁrst wave and the second wave across 26 public health units in Ontario. We also explored whether a
high testing rate was associated with a large CFR decrease.
Results: The ﬁrst wave CFR ranged from 0.004 to 0.146, whereas the second wave CFR ranged from
0.003 to 0.034. The pooled RR estimate of second wave COVID-19 case fatality, compared with ﬁrst wave,
was 0.24 (95% CI: 0.19-0.32). Additionally, COVID-19 testing percentages were not associated with the
estimated relative risk (P=0.246).
Conclusions: The COVID-19 CFR decreased signiﬁcantly in Ontario during the second wave, and COVID-19
testing was not a driving factor for this decrease.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction
The COVID-19 pandemic continues to surge globally. Recently,
many countries experienced a substantial second wave of COVID19 (James et al., 2021). While there were much higher infection
numbers and in some countries more deaths than those in the
ﬁrst wave, a substantial decrease in the case fatality rate (CFR)
was observed (https://www.ft.com/content/b3801b63- fbdb- 433b9a46-217405b1109f). Interestingly, researchers have reported that
CFR decreased during the ﬁrst wave indicating that COVID-19
severity might lessen with time (Schmidt et al., 2021; Anesi et al.,
2021). However, prior studies only examined declining CFR in

hospitalized patients during the ﬁrst wave. Because there was
a higher likelihood of detecting asymptomatic and mildly symptomatic infections during the second wave, health experts suspect that increased testing numbers may partially explain the
decline in CFR (https://www.ft.com/content/b3801b63-fbdb-433b9a46-217405b1109f). However, little is known regarding the CFR
changes between the ﬁrst and second waves at the population
level or whether high testing rates were associated with the CFR
decrease. Determining the magnitude of the CFR decrease and the
association between COVID-19 testing rates and CFR changes could
have implications for future public health interventions.
Methods
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We conducted a cross-sectional study using publicly reported
COVID-19 cases, deaths, and tests available on the Ontario
Public Health website as of February 10, 2021 (https://covid19.ontario.ca/data). In Ontario, Canada, the peak 7-day moving av-
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Figure 1. COVID-19 case fatality in the ﬁrst versus the second wave in Ontario, Canada
RR: relative risk

Table 1
Unadjusted and adjusted odds ratio for the analyses using individual-level data

erage during the ﬁrst and second waves was 640 in April 2020
and 4249 in January 2021. As the number of new cases in Ontario dropped below 200 per day between late June and early
September 2020, we used July 31 to separate the ﬁrst and second waves. We also conducted sensitivity analyses using June 30,
2020, and August 31, 2020, as the cut-off dates. We determined
the CFR per public health unit (PHU) for both the ﬁrst and second waves, deﬁned as the number of deaths divided by the number of new cases. PHUs which had no COVID-19 deaths in the
ﬁrst or second wave were excluded. We calculated the relative risk
(RR) of COVID-19 CFR between the 2 waves (the second versus
the ﬁrst wave) and the corresponding 95% CI for each PHU. Using a random-effects meta-analysis with inverse variance weighting, we estimated the pooled RR on population-level CFR across
PHUs. Using meta-regression techniques, we regressed the logarithm form of effect size by the second wave testing percentage
(the number of tests divided by the total population). Acknowledging that second-wave patients were younger than in the ﬁrst wave,
we also analyzed individual-level data. Applying hierarchical generalized linear models, we estimated the adjusted odds ratio (AOR),
clustering by PHUs and controlling for patient age, wave, and testing percentage.

Individual-level analysis

2

nd

wave (ref: 1

st

wave)

Public health unit-level testing
percentage (continuous variable)

Unadjusted

Model 1∗

Model 2∗

0.21
(0.20, 0.23)

0.42
(0.39, 0.44)

0.42
(0.39, 0.44)
0.38
(0.05, 2.81)

∗
Model 1 adjusted for patient age and wave; model 2 adjusted for age, wave,
and public health unit-level second-wave testing percentage.

was substantial variation in the RRs between the 2 waves across
PHUs (Figure 1). The pooled RR estimate of second wave COVID19 case fatality, compared with ﬁrst wave, was 0.24 (95% CI: 0.190.32). Meta-regression models showed that COVID-19 testing percentages were not statistically signiﬁcantly associated with the estimated RR (P=0.246) despite a trend that the higher the percentage of COVID-19 testing, the smaller the effect size, i.e., RR close
to 1 (Appendix Figure). Individual-level data analyses, adjusting for
age, revealed that the AOR of the second wave, compared with the
ﬁrst wave, was 0.41 (95% CI: 0.38-0.43; Table 1). Sensitivity analyses using 2 different dates to deﬁne the second wave reached similar conclusions (data not shown).

Results
Of the 34 PHUs in Ontario, Canada, 26 PHUs had more than 1
death in the ﬁrst and second waves and were therefore included
in the analyses. The ﬁrst wave CFR ranged from 0.004 to 0.146,
whereas the second wave CFR ranged from 0.003 to 0.034. There

Discussion
We found that the COVID-19 CFR decreased signiﬁcantly
in Ontario during the second wave. Young age contributed
190
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to this decrease, but high COVID-19 testing was not a driving factor. Potential reasons for the decrease in COVID-19 CFR
may be attributed to improvement in clinical care: for example, there was increasing evidence to support corticosteroid
use (Chris Baraniuk, 2021), and Canada approved effective
treatments, such as Remdesivir and Bamlanivimab in July and
November 2020, respectively (https://www.canada.ca/en/healthcanada/services/drugs-health-products/covid19-industry/drugsvaccines-treatments/authorization/list-drugs.html).
Additionally,
our ﬁndings suggest that SARS-CoV-2, despite becoming more
transmissible, might decline in virulence over time. Indeed, researchers have demonstrated a dynamic shift in SARS-CoV-2
variants to those with increased survival (Esper et al., 2021).
As SARS-CoV-2 genome sequencing in Ontario during the study
period is lacking, research on the CFR of variants is needed.
Increased public awareness during the second-wave period, such
as compliance with wearing masks, could also decrease the viral
inoculum, leading to milder and asymptomatic infection manifestations (Gandhi et al., 2020). While our random-effects models
account for PHU-level characteristics, we acknowledge that we are
unable to control for confounding factors. To evaluate COVID-19
intervention programs, researchers and policy decision-makers
should account for the changes in COVID-19 severity.
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